High materiality8/10
PTC Therapeutics upgraded to Outperform from Market Perform at Leerink
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Leerink Partners upgrades PTCT to Outperform with a new target of $98; current price $66.38.
- Target: $98
- Posted price: $66.38
- Analyst: Leerink Partners
Key facts
- 01
Target: $98
- 02
Posted price: $66.38
- 03
Analyst firm: Leerink Partners
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.